Rhythm Biosciences (ASX:RHY)
We spoke to Dr. David Atkins, CEO of Rhythm Biosciences (ASX: RHY), about the company’s ColoStat product, a simple, affordable blood-based test for the detection of colorectal cancer.
The clinical data for ColoStat has been great and under David Atkin’s leadership in 2024 the company has now created a multiplex test to meet relevant regulatory standards. The company can now proceed to seek regulatory approval to market the test. Given the prevalence of colorectal cancer, the upside for ColoStat is significant, in our view.
Also check out some of our other interviews with Life Sciences companies!
Looking for the Best ASX Life Sciences Stocks to invest in right now?
Check our ASX buy/sell tips
